GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter

 
• By Jessica Merrill
  
Slowdown, word cube with background.
Sales of GSK's big growth driver Shingrix have slowed in the second quarter • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business